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Background: Pulmonary metastasectomy is a standard method for
treatment of selected pulmonary metastases cases. Nevertheless,
because prognosis for patients with lung metastases from esophageal
cancer who have undergone pulmonary metastasectomy is poor,
candidates for this method of treatment are rare. Therefore, the
efficacy of surgical treatment for pulmonary metastatic lesions from
esophageal cancer has not been thoroughly examined.
Methods: Between March 1984 and May 2006, 57 patients under-
went resection of pulmonary metastases from primary esophageal
cancer. These cases were registered in the database developed by the
Metastatic Lung Tumor Study Group of Japan and were retrospec-
tively reviewed from the registry. After excluding eight cases
because of missing information, we reviewed the remaining 49 cases
and examined the prognostic factors for pulmonary metastasectomy
for metastases from esophageal cancer.
Results: There were no perioperative deaths. After pulmonary
metastasectomy, disease recurred in 16 (33%) of the 49 patients. The
overall 5-year survival was 29.6%. Median survival time was 18
months. The survival of patients with a disease-free interval (DFI)
less than 12 months was significantly lower than patients with a DFI
greater than 12 months. Through multivariate analysis, we identified
DFI as a clinical factor significantly related to overall survival (p 
0.04).
Conclusions: We identified that patients with a DFI less than 12
months who underwent pulmonary metastasectomy for metastases
from esophageal cancer had a worse prognosis. Pulmonary metas-
tasectomy for esophageal cancer should be considered for selected
patients with a DFI 12 months.
Key Words: Esophageal cancer, Pulmonary metastasis, Metastasec-
tomy.
(J Thorac Oncol. 2008;3: 1046–1049)
Pulmonary metastasectomy is a standard method of treat-ment for selected pulmonary metastases cases.1 When
patients are appropriately selected for this treatment, the
overall 5-year survival after pulmonary metastasectomy is
about 30 to 40%.1,2 In general, because prognosis for patients
who have undergone this method of treatment is poor with
disease frequently recurring, pulmonary metastasectomy is
not a frequently chosen method of treatment for lung metas-
tases from esophageal cancer. Consequently, survival after
surgery for pulmonary metastases from esophageal cancer
has not been thoroughly examined. In Japan, the annual
report by the Japanese Association for Thoracic Surgery does
not document patients who underwent metastasectomy for
metastasized esophageal cancer.3 Because the outcome of
pulmonary metastasectomy for metastases from esophageal
cancer has not been thoroughly investigated, it is controver-
sial whether surgery is an effective treatment for metastatic
esophageal cancer. To identify prognostic factors of pulmo-
nary metastasectomy for metastases from esophageal cancer,
in the present study, we reviewed cases registered in the
Metastatic Lung Tumor Study Group of Japan database of
patients who underwent metastasectomy for metastasized
esophageal cancer.
PATIENTS AND METHODS
The Metastatic Lung Tumor Study Group of Japan
developed a database for registration of lung metastases
cases. These patients all underwent surgical resection. The
database documents the following parameters: gender; age;
histology; status of the primary tumor; treatment for the
primary tumor; date of primary surgery; kind of surgery;
curability; date of metastasis; disease-free interval (DFI);
side, size and numbers of resected metastases; date of metas-
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tasectomy; and follow-up. Between March 1984 and May
2006, 57 patients underwent resection of pulmonary metas-
tases from primary esophageal cancer. These cases were
registered in the Metastatic Lung Tumor Study Group of
Japan database and were retrospectively reviewed from the
registry. Preoperative examination, surgical indication, and
operative procedure were at the discretion of each institution.
After excluding eight cases because of missing informa-
tion such as number of resected metastases, age, or DFI, we
examined the remaining 49 cases (46 males and 3 females) in
our study. Surgery alone for the primary tumor was performed in
26 cases (53%), surgery and chemoradiotherapy were performed
in 7 cases (14%), surgery and radiotherapy were performed in 6
cases (12%), surgery and chemotherapy were performed in 3
cases (6%), radiotherapy alone was performed in 2 cases (4%),
and treatment data were not available for 5 cases (10%). We
examined the following variables (Table 1): age (70 or 70),
number of resected metastases (solitary or multiple), resected
side (unilateral or bilateral), tumor size (3 or 3cm), DFI
(12 or 12 months), surgical procedure (partial resection,
segmentectomy, or lobectomy), and curability (complete or
incomplete).
The present study was analyzed using anonymized data
that were collected in each institution. Therefore, informed
consent was not specifically obtained and institutional review
board approval was not necessary.
Statistical Analysis
Overall survival was analyzed by the Kaplan-Meier
method, and differences in variables were calculated by the
log-rank test. The date of pulmonary resection was defined as
the starting point. Cox’s proportional hazards model was used
for multivariate analysis. The data were calculated using
version 5.0 of the StatView software package (SAS Institute
Inc, Cary, NC). A p value of less than 0.05 was defined as
indicative of statistical significance.
RESULTS
The median interval between treatment of esophageal
cancer and diagnosis of pulmonary metastasis (disease-free
interval) was 14 months (range: 0–124 months). There were
no perioperative deaths. The median age of patients at the
time of pulmonary metastasectomy was 65 years (range:
35–82). The median number of resected metastatic lesions
per patient was one (range: 1–5). The metastases ranged in
size from 0.4 to 5.5 cm, and the median size was 2.0 cm. The
metastases were squamous cell carcinoma in 48 cases and
adenocarcinoma in one case. The surgical procedure was
wedge resection in 23 cases (47%), lobectomy in 16 cases
(33%), segmentectomy in 8 cases (16%), and bilobectomy in
2 cases (4%). The median follow-up period after the first
pulmonary resection was 18 months (range: 0–206 months).
Recurrence developed in 16 (33%) of the 49 patients. Recur-
rences were as follows: lung, nine; lymph node, three; neck,
one; distant metastasis, one; stomach, one; and unknown,
two. The overall 5-year survival after pulmonary metastasec-
tomy was 29.6% (Figure 1). Median survival time was 27
months. We investigated the relationships between prognos-
tic factors and survival (Table 1). Patients with a DFI less
than 12 months had a significantly worse prognosis, as
assessed by survival rates, than patients with a DFI greater
than 12 months (Figure 2). Multivariate analysis of these
variables was performed using Cox’s proportional hazards
model for disease-specific survival. A DFI less than 12
months was shown to be an independent prognostic factor
(p  0.04) (Table 2). At the time of submission, 28 patients
examined in our study have died. Although 23 patients died
of esophageal cancer, 7 patients were not available for recur-
rent sites. Five patients have died of other diseases (two cases
TABLE 1. Survival of 49 Patients According to Clinical
Factors of Pulmonary Metastases
Variables n (%) 5-yr Survival (%) p
Age (yr)
70 13 (27) 32.9 0.928
70 36 (73) 27.8
Number
Solitary 39 (80) 27.4 0.797
Multiple 10 (20) 42.9
Resected side
Unilateral 44 (90) 29.3 0.621
Bilateral 5 (10) 30.0
Tumor sizea
3 cm 10 (21) 40.0 0.640
3 cm 38 (79) 26.7
DFI
12 mo 28 (57) 39.2 0.048
12 mo 21 (43) 15.7
Surgical procedure
Partial and
segment
31 (63) 36.4 0.338
Lobectomy 18 (37) 22.9
Curability
Complete 45 (92) 31.4 0.990
Incomplete 4 (8) 25.0
a No cases were available.
DFI, disease-free interval.
FIGURE 1. Overall survival of the 49 patients after pulmo-
nary metastasectomy. The 5-year survival was 29.6%.
Journal of Thoracic Oncology • Volume 3, Number 9, September 2008 Pulmonary Metastasectomy for Esophageal Cancer
Copyright © 2008 by the International Association for the Study of Lung Cancer 1047
were pneumonia, two cases were cerebral infarction, and one
case was myocardial infarction).
DISCUSSION
Patients who are candidates for pulmonary metastasec-
tomy for metastases from esophageal cancer are a minority.
Analysis of the outcomes of surgery for pulmonary metasta-
ses from esophageal cancer has not been published. Quint et
al.4 showed that 29 of 147 (20%) patients with newly diag-
nosed metastasized esophageal cancer had lung metastasis.
Although autopsy studies showed that the frequency of
esophageal lung metastasis was 50%,5 there was not a high
percentage of esophageal cancer relapse after esophagec-
tomy. Kyriazanos et al.6 revealed that 12 of 151 (8%) patients
who underwent a curative esophageal resection had lung
metastases. Within our study the number of adenocarcinoma
of the esophagus was very small. Because the frequency of
adenocarcinoma of the esophagus is low in Japan, we do not
speculate about the scarce incidence of lung metastasis from
adenocarcinoma of the esophagus.
Matsubara et al. showed that 38 of 230 patients (17%)
who underwent surgery for esophageal cancer with extended
lymph node dissection had distant metastases and 14 (6%)
patients had lung metastases. In their article, the outcomes
after recurrence were dismal, and no patients were alive 5
years after detection of recurrence. Nevertheless, they
showed that the 1-year survival of the patients who had
recurrent lesions and were treated with resection and adjuvant
therapy was 83%. They concluded that when recurrent le-
sions were localized macroscopically, surgical removal of the
recurrent lesions was an effective treatment.7 Through our
analysis, we found a 5-year survival of 29.6% after pulmo-
nary metastasectomy, which indicates that pulmonary metas-
tasectomy is a promising treatment for metastases from
esophageal cancer. Nevertheless, as it is not easy to differ-
entiate esophageal metastases from primary lung squamous
cell carcinomas, it is possible that our data might include
primary lung squamous cell carcinoma. Survival after metas-
tasectomy might be lower than what our data indicate. Virgo
et al mentioned that genetic markers are needed to confidently
distinguish between metastases and primary solitary nod-
ules.8 Further investigation is needed to clarify this matter.
An article from the international registry of lung me-
tastases states that the 5-year survival was 37% after pulmo-
nary metastasectomy. In addition, the article showed that
among cases of complete resection, the 5-year survival was
33% for patients with a DFI of 0 to 11 months and 45% for
those with a DFI of more than 36 months. Furthermore, the
5-year survival was 43% for single lesions and 27% for 4 or
more lesions.1 DFI and number of pulmonary metastases are
significant prognostic factors. Because our present data show
that the median DFI is 14 months, we categorized DFI as
12 or 12 months. Regarding the DFI, our study suggests
that patients with a DFI less than 12 months have a poor
prognosis. Osugi et al. showed that 83% of recurrences
presented within 24 months after esophagectomy and that the
chance of survival of patients whose disease recurred within
24 months after esophagectomy was better than that of
patients who suffered recurrence within 24 months. Regard-
ing follow-up studies after esophagectomy, meticulous care
should be taken to detect hematogenous recurrence.9
In general, incomplete resection is a dismal prognostic
factor in lung metastasectomy. We could not demonstrate
whether surgical curability is a prognostic factor. McDonald
et al. reported that incomplete resection appeared to have no
influence on overall survival in metastatic breast cancer. They
suggested that this could be due to the systemic nature of the
disease at the time of thoracotomy with unsuspected occult
metastasis in other areas.10 Nevertheless, in our study, only
four patients underwent incomplete resection. Because the
report from The International Registry of Lung Metastases
stated that cases with incomplete resection clearly had worse
prognoses,1 we speculate that patients with lung metastases
from esophageal cancer have the same tendency.
Although our present study was multi-institutional, we
could not analyze in detail all of the records for each patient.
From this point of view, because our findings were based on
a limited number of cases, pulmonary metastasectomy for
lung metastases from esophageal cancer is still highly con-
troversial. Nevertheless, we identified that patients with a DFI
less than 12 months had a worse prognosis, as assessed by
FIGURE 2. Overall survival after pulmonary metastasectomy
according to DFI. Survival curves of patients with DFI 12
months and 12 months. DFI, disease-free interval.
TABLE 2. Relationships of Individual Variables to Survival
(Cox’s Proportional Hazards Model)
Variable Risk Ratio 95% CI p
70 yr 1.01 0.41–2.50 0.983
Multiple metastasis 1.67 0.30–9.19 0.557
Bilateral metastasis 1.19 0.19–7.53 0.853
Tumor size 3 cm 0.76 0.25–2.35 0.635
DFI 12 mo 2.30 1.04–5.09 0.040
Partial and segment 0.60 0.22–1.65 0.180
Incomplete resection 1.00 0.22–4.56 0.881
CI, confidence interval; DFI, disease-free interval.
Shiono et al. Journal of Thoracic Oncology • Volume 3, Number 9, September 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer1048
survival rates, than patients with a DFI greater than 12
months.
Consequently, although metastases from esophageal
cancer are a minority, we think that pulmonary metastasec-
tomy for esophageal cancer should be considered for selected
patients with a DFI 12 months. As this study is small,
further clinical studies will be needed.
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